**Table S3.** **Anti-tumor activity in a panel of human KRASG12C xenograft models**

|  |  |  |
| --- | --- | --- |
| **Models** | **Cancer type** | **Tumor volume, % change (mean ± sem)†** |
| LXFA-592 | NSCLC | -99 ± 1; n=3 |
| NCI-H358\* | -96 ± 1; n=8 |
| CTG-1680 | -94 ± 3; n=3 |
| CTG-2539 | -89 ± 3; n=3 |
| LUN055 | -87 ± 7; n=3 |
| LXFA-983 | -84 ± 6; n=3 |
| LXFA-923 | -82 ± 8; n=3 |
| CTG-2011 | -80 ± 4; n=3 |
| LXFL-1072 | -76 ± 7; n=3 |
| CTG-0192 | -73 ± 6; n=3 |
| CTG-0828 | -71 ± 4; n=3 |
| LXFE-2324 | -68 ± 11; n=3 |
| CTG-2210 | -68 ± 1; n=3 |
| LXFA-2155 | -64 ± 5; n=3 |
| CTG-2579 | -63 ± 3; n=3 |
| CTG-2487 | -58 ± 4; n=3 |
| CTG-2751 | -37 ± 12; n=3 |
| LUN092 | -37 ± 5; n=10 |
| NCI-H2030\* | -23 ± 8; n=3 |
| ST2972 | -9 ± 13; n=10 |
| LXFA-1335 | 2 ± 9; n=3 |
| LXFE-1022 | 20 ± 18; n=3 |
| CTG-2536 | 176 ± 46; n=17 |
| NCI-H2122\* | 240 ± 41; n=3 |
| CTG-2026 | 418 ± 84; n=3 |
| ST1384 | CRC | -79 ± 12; n=5 |
| CXF-2163 | -75 ± 4; n=3 |
| SW837\* | -60 ± 6; n=5 |
| CRC024 | -33 ± 5; n=8 |
| CTG-0387 | -25 ± 13; n=2 |
| ST4859 | -12 ± 14; n=5 |
| ST230 | -7 ± 7; n=5 |
| STF167 | 47 ± 20; n=5 |
| CRC022 | 56 ± 30; n=8 |
| ST3235 | 59 ± 17; n=5 |
| ST046 | 63 ± 61; n=3 |
| ST094 | 102 ± 27; n=5 |
| CTG-1489 | 113 ± 49; n=3 |
| ST4368 | 187 ± 68; n=3 |
| ST026 | 403 ± 159; n=3 |

\*Cell line-derived xenograft models. All others are models derived from patients.

**†**Percentage of tumor volume change from baseline was calculated as described in Materials and Methods. RMC-6291 was administered orally daily at 200 mg/kg